2025 Annual Shareholders' Meeting Results

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

2025 Annual Shareholders’ Meeting Results

Auckland, New Zealand, 21 August 2025 – Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company’s annual shareholders’ meeting held today were passed.

The seven resolutions were:
Resolution 1: To re-elect Neville Mitchell as a Director.
Resolution 2: To re-elect Lewis Gradon as a Director.
Resolution 3: To re-elect Lisa McIntyre as a Director.
Resolution 4: To re-elect Cather Simpson as a Director.
Resolution 5: To elect Mark Cross as a Director.
Resolution 6: To authorise the Directors to fix the fees and expenses of the company’s auditor.
Resolution 7: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon as set out in the Notice of Annual Shareholders’ Meeting 2025.

All resolutions were decided by poll. The details of the total number of votes cast online, in person or by proxy on the polls were as follows:

Resolution Votes:
Resolution 1: Re-election of Neville Mitchell as a Director.
For: 429,216,814 (97.36%); Against: 11,652,978 (2.64%); Abstain: 1,299,617
Resolution 2: Re-election of Lewis Gradon as a Director.
For: 441,426,824 (99.97%); Against: 139,173 (0.03%); Abstain: 601,896
Resolution 3: Re-election of Lisa McIntyre as a Director.
For: 430,486,886 (97.37%); Against: 11,642,888 (2.63%); Abstain: 39,635
Resolution 4: Re-election of Cather Simpson as a Director.
For: 441,889,235 (99.95%); Against: 243,087 (0.05%); Abstain: 37,087
Resolution 5: Election of Mark Cross
For: 437,480,939 (98.98%); Against: 4,489,818 (1.02%); Abstain: 198,652
Resolution 6: Approval of auditors' fees and expenses
For: 437,099,574 (99.05%); Against: 4,211,623 (0.95%); Abstain: 858,212
Resolution 7: Grant of discretionary long term variable remuneration instruments to Lewis Gradon
For: 431,000,052 (97.82%); Against: 9,625,215 (2.18%); Abstain: 963,529

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Contacts

Media
Karen Knott
GM Corporate Communications
[email protected]
+64 (0) 21 713 911

Investors
Dan Adolph
Head of Investor Relations
[email protected]
+64 (0) 22 511 4050


Authorised by Raelene Leonard, General Counsel & Company Secretary.

---

Announcement PDF